Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

February 28, 2025

NEWS RELEASE

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive Officer
(Securities code: 4891; Growth4 Market)

Notice of Change in Fiscal Year End (Financial Year End)

TMS Co., Ltd. (the "Company") hereby announces that its Board of Directors, at a meeting held today, resolved to change its fiscal year end (the last day of the financial year), subject to approval of the "Partial Amendment to the Articles of Incorporation" at the 21st Ordinary General Shareholder Meeting to be held in May 2025

1. Reason for the Change

The Company's fiscal year currently runs from March 1st to the last day of February of the following year. However, we will change our fiscal year to run from January 1 to December 31st of each year in order to align our fiscal year with global standards and to improve the efficiency of our business operations through timely and appropriate disclosure of information to investors, including those overseas.

2. Details of the Change in Fiscal Year End

Current : February 28 of every year

After change : December 31 of every year

The 22nd fiscal year, which will be the transitional period for the change in fiscal year end, is scheduled to have a ten-month accounting period from March 1, 2025 to December 31, 2025.

3. Future outlook

The Company does not disclose forecasts of earnings figures. For the 22nd fiscal year, which is the transitional period for the change in fiscal year end, the Company plans to announce a range of estimated operating expenses in its earnings report for the fiscal year ending February 2025, which is scheduled to be disclosed in April 2025.

4. Partial Amendment to the Articles of Incorporation

The proposed amendment to the Articles of Incorporation in line with the change in the fiscal year-end (the last day of the financial year) will be disclosed without delay after the resolution of the 'Partial Amendment to the Articles of Incorporation' as an agenda item at the 21st Ordinary General Shareholder Meeting to be held in late May 2025, at the Board of Directors meeting scheduled to be held in April 2025.

About TMS Co., Ltd.

TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative medicines for the treatment of serious diseases in areas of high unmet medical need. The Company's pipeline consists of a family of small molecule compounds called SMTPs (Stachybotrys Microspora Triprenyl Phenols) derived from a fungus. TMS' lead program, TMS-007 (JX10), has demonstrated efficacy and safety in its Phase 2a study for the treatment of acute ischemic stroke. The Company's robust pipeline also includes programs in resistant or uncontrolled hypertension, acute kidney injury, and spinal cord injury. TMS continues to explore new pipeline products by leveraging its established partnerships with leading academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit https://www.tms-japan.co.jp/en/

Investor and Media Contact:
ir@tms-japan.co.jp

End